Top News

Obesity is the accumulation of excess fat in the body, which can cause serious health problems. This condition increases the risk of diseases such as diabetes, heart disease, hypertension and specific types of cancer. Many causes such as diet, lack of physical activity, heredity and some drugs can cause obesity. In the meantime, the new Easo algorithm Semaglutide recommends the management of obesity in heart disease, diabetes and cardiovascular patients, guidelines say that obesity management should be long-term, multi-tailored and personalized.

The European Association for Study of Obesity (EASO) has issued a new management algorithm. Obesity is an chronic, recurrent disease. The scientific consent that requires continuous, long -term care, strengthens. Guidelines create a comprehensive, evidence -based frame that passes through short -term interventions to personalized and multi -dimensional management policy for patients.

Diet to reduce the gas -filled gas in the stomach, consumption of ‘foods’ will disappear in a few minutes.

Easo rewards the modern care model built on the base of the main lifestyle intervention such as algorithms nutrition, physical activity and behavioral therapy. Accepting that lifestyle changes are often inadequate for sustainable management, obesity management drugs (OMMS) and if appropriate, the integral role of metabolic barretic surgery is detailed.

An important part of the new frame is guidance on planning treatment according to the patient’s specific health complications. Algorithm reviewed the spectrum of accredited OMMS, taking into account their different functionality and benefits. These included Orlistat, Naltrex/Bupropian, Lirglutide, Semglutide and Tirzepatide. In the guidelines, it is stated that semaglutide and twespatide should be considered as the preferred OMM when the body needs to lose weight.

Easo algorithms were known as a pillar for a wide range of patients with obesity and many-existing health conditions, as it loses more than 10% weight and has proven benefits to reduce mortality and get rid of type 2 diabetes.

Heart disease: Sumglutide was the only recommended OMM due to the ease of reducing the main adverse cardiovascular event.
Heart failure: Both semaglutide and twesterpide should be considered in the first class treatment.
Knee osteoarthritis: Semaglutide should be considered as the first grade treatment as it reduces the pain associated with this condition.
Type 2 diabetes or prediabies: Semglutide and Tirzeptide are the first choice drugs, and lirglutide and naltrexone-Bupropane are the second grade treatment.

For patients with obesity and liver disease or oxcorative sleep apnea, Tirzepatide is the recommended OMM.
Algorithm emphasized that obesity management should be continuous, as evidence has shown that closure of medication can often increase weight. This approach supports the change in the direction of treating obesity, just like other chronic diseases, using the right combination of lifestyle adjustments and the proper combination of pharmacotherapy to improve the patient’s health and standard of living.

Four foursomes bring ashamed of the mouth? Then start consuming these 2 rupees of food in the kitchen today and see the maximum